Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial von Hochhaus, A, Saglio, G, Hughes, T P, Larson, R A, Kim, D-W, Issaragrisil, S, le Coutre, P D, Etienne, G, Dorlhiac-Llacer, P E, Clark, R E, Flinn, I W, Nakamae, H, Donohue, B, Deng, W, Dalal, D, Menssen, H D, Kantarjian, H M

Volltext

PHASE I/II STUDY OF THE TUMOUR-TARGETING HUMAN L19- IL2 MONOCLONAL ANTIBODY-CYTOKINE FUSION PROTEIN IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA von Johannsen, M, Roemer, A, Roigas, J, Curigliano, G, Spitaleri, G, Giovannoni, L, Menssen, H.D, Zardi, L, Milani, A, Boselli, S, Neri, D, De Braud, F

Volltext

Cyclophosphamide, adriamycin and dexamethasone (CAD) is a highly effective therapy for patients with advanced multiple myeloma von Szelényi, H., Kreuser, E. D., Keilholz, U., Menssen, H. D., Keitel-Wittig, C., Siehl, J., Knauf, W., Thiel, E.

Volltext

Cyclophosphamide, liposomal doxorubicin and dexamethasone (CLAD) is safe and efficacious in multiple myeloma von Szelényi, H., Siehl, J., Menssen, H.D., Thiel, E., Keilholz, U.

Volltext